June 18, 2020 – Portland, OR.
Cromos Pharma, an international CRO, is pleased to announce unprecedented recruitment in a phase IIb trial in patients with moderate to severe COVID-19 infection. It has successfully recruited over 300 patients in under two months to the trial.
“We are very proud of our team for this fantastic accomplishment,” said Stephanie Finnegan, Cromos Pharma's Chief Operating Officer. “Running studies in hospital-based critical care settings, in patients with life-threatening conditions always pushes the boundaries in clinical trials. Doing this entirely remotely, and during a pandemic, in medical facilities operating well beyond capacity has posed a tremendous challenge, and is a clear testament to our staff’s professionalism and dedication,” she continued.
The trial, one of several COVID-19 studies that the company is managing
, is testing the efficacy of treatments in patients with moderate to severe COVID-19.
“As researchers around the world continue to seek effective treatments and a vaccine, we are honored to be part of the global fight against this devastating pandemic,” added Dr Vlad Bogin, Cromos Pharma's CEO. “Being able to challenge ourselves during this time of uncertainty and to achieve record-breaking results is an important moment for our company.”
Contact Cromos Pharma by emailing firstname.lastname@example.org
About Cromos Pharma
Cromos Pharma is an international CRO in its 16th year of delivering with expertise a fully integrated suite of clinical trial management services, in both early and late clinical phases, and across a broad range of therapeutic areas. Established in 2004, Cromos™ Pharma is a US-based company with strong regional presence in Central and Eastern Europe, Russia and CIS countries. The company clinical trial-related services include regulatory consulting and approval, medical writing, project management, venue and site feasibility, selection and recruitment strategy, clinical and medical monitoring, product registration, and post-market services. Cromos™ Pharma, LLC is a privately-owned company.